Australian medicine co Orthocell hits record high on US FDA clearance

Orthocell

02/12/2024 04:45

** Shares of Orthocell  OCC.AX  rise as much as 26.5% to a
record high of A$1.025
    ** The regenerative medicine company completes U.S. FDA
510(k) regulatory study, validating Remplir as a safe and
effective biological medical device
    ** Remplir is a biological medical device for use in the
surgical repair of peripheral nerves
    ** Stock has risen 97.6% this year, including session's
moves

    

 (Reporting by Namrata Verma in Bangalore)
 ((Namrata.Verma@thomsonreuters.com;))